RxSight (RXST) Income from Non-Controlling Interests (2020 - 2024)
RxSight (RXST) posted Income from Non-Controlling Interests of $155000.0 for Q4 2024, up 3000.0% on a QoQ basis from $5000.0 in Q3 2024, and up 89.02% year-over-year from $82000.0 in Q1 2024.
RxSight (RXST) Income from Non-Controlling Interests (2020 - 2024) Analysis & Trends
RxSight's Income from Non-Controlling Interests history runs 5 years deep, the most recent figure standing at $155000.0 for Q4 2024.
- Quarterly Income from Non-Controlling Interests rose 89.02% year-over-year to $155000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $170000.0 (up 88.89% YoY) and the FY2025 annual result came in at $18000.0, down 89.47% from the prior year.
- Income from Non-Controlling Interests was $155000.0 for Q4 2024 at RxSight, up from $5000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $155000.0 in Q4 2024 and bottomed at -$87000.0 in Q4 2022.
- A 5-year average of $10473.7 and a median of $3000.0 in 2020 frame the typical range for Income from Non-Controlling Interests.
- Peak annual rise in Income from Non-Controlling Interests reached 400.0% in 2022, while the deepest fall reached 8800.0% in 2022.
- RxSight's Income from Non-Controlling Interests stood at $2000.0 in 2020, then plunged by 50.0% to $1000.0 in 2021, then plunged by 8800.0% to -$87000.0 in 2022, then soared by 194.25% to $82000.0 in 2023, then surged by 89.02% to $155000.0 in 2024.
- Business Quant data shows RXST's Income from Non-Controlling Interests at $155000.0 in Q4 2024, $5000.0 in Q3 2024, and $5000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | - |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 16.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -2.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -5.85 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 22.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | RxSight | 221.81 Mn | -196.39 Mn | 23.50 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 155,000.00 |
| Sep 30, 2024 | 5,000.00 |
| Jun 30, 2024 | 5,000.00 |
| Mar 31, 2024 | 5,000.00 |
| Dec 31, 2023 | 82,000.00 |
| Sep 30, 2023 | 2,000.00 |
| Jun 30, 2023 | 2,000.00 |
| Mar 31, 2023 | 4,000.00 |
| Dec 31, 2022 | -87,000.00 |
| Sep 30, 2022 | 5,000.00 |
| Jun 30, 2022 | 4,000.00 |
| Mar 31, 2022 | 3,000.00 |
| Dec 31, 2021 | 1,000.00 |
| Sep 30, 2021 | 1,000.00 |
| Jun 30, 2021 | 1,000.00 |
| Mar 31, 2021 | 2,000.00 |
| Dec 31, 2020 | 2,000.00 |
| Sep 30, 2020 | 3,000.00 |
| Jun 30, 2020 | 4,000.00 |